---
title: "Amphastar Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $22, Implies 1% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291152870.md"
description: "Amphastar Pharmaceuticals' 12-month average price target was lowered from $22.83 to $22 by six analysts, implying a 1% upside based on the June 26 closing price. The consensus rating remains 'Hold', with ratings consisting of zero Buys, six Holds, and one Sell."
datetime: "2026-06-29T13:20:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291152870.md)
  - [en](https://longbridge.com/en/news/291152870.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291152870.md)
---

# Amphastar Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $22, Implies 1% Upside

-   According to estimates from 6 analysts, Amphastar Pharmaceuticals, Inc. stock's average price target has fallen from $22.83 to $22, with forecasts ranging from $19 to $30 per share
-   Based on the Jun. 26 closing price, the updated target implies approximately 1% potential upside
-   Consensus rating remains at “Hold” across 7 covering analysts, with 0 Buys, 6 Holds and 1 Sells

Explore more price target data and ratings for Amphastar Pharmaceuticals, Inc. on the , and track all previous and future analyst recommendations for Amphastar Pharmaceuticals, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [AMPH.US](https://longbridge.com/en/quote/AMPH.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Amphastar Pharmaceuticals subsidiary receives FDA warning letter over CGMP issues at California facility](https://longbridge.com/en/news/292050282.md)
- [Israel "Izzy" Englander increased his position in this pharma stock by 780%. Does he know something Wall Street doesn't?](https://longbridge.com/en/news/293842675.md)
- [Tarsus Pharmaceuticals (TARS) Could Be 38% Undervalued Following Cautious Earnings Expectations](https://longbridge.com/en/news/294318126.md)
- [Is Extra Space Storage (EXR) Reasonable Near Fair Value?](https://longbridge.com/en/news/294274088.md)
- [Does DoubleVerify (DV)ʼs Cautious Revenue Outlook Hint At A Shift In Its Growth Narrative?](https://longbridge.com/en/news/293853094.md)